AN2 Therapeutics Reports Q2 Earnings, Net Loss Improves to $6.5M

AN2 Therapeutics reported a Q2 net loss of $6.5 million, a significant improvement from $14.4 million in the same period last year. Operating expenses decreased to $7.2 million from $15.9 million. The company has $71.2 million in cash, down from $92.1 million at the end of 2024, but believes it can fund operations for at least the next 12 months. AN2 Therapeutics is focused on advancing its pipeline of boron-based compounds and securing additional funding to support its research and development activities.